Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesity and chronic kidney disease at the 84th Scientific Sessions of the American Diabetes Association
18 juin 2024 08h00 HE
|
Novo Nordisk A/S
FLOW kidney outcomes trial data evaluating efficacy and safety of once-weekly semaglutide 1.0 mg in people with type 2 diabetes1SELECT cardiovascular outcomes trial data evaluating efficacy and safety...
Novo Nordisk A/S - share repurchase programme
17 juin 2024 08h26 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
10 juin 2024 08h15 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
03 juin 2024 10h05 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 3 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
27 mai 2024 08h49 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 27 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S - share repurchase programme
17 mai 2024 10h20 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 17 May 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
15 mai 2024 07h23 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
13 mai 2024 11h49 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 mai 2024 11h31 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 8 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...
Trading in Novo Nordisk shares by board members, executives and associated persons
06 mai 2024 15h02 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons...